Comparative Pharmacology
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus STILPHOSTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PREMPHASE PREMARIN CYCRIN 14 14 versus STILPHOSTROL.
PREMPHASE (PREMARIN;CYCRIN 14/14) vs STILPHOSTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PREMPHASE combines conjugated estrogens (PREMARIN) and medroxyprogesterone acetate (CYCRIN). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ), which regulate gene transcription and produce effects in tissues such as the endometrium, breast, and bone. Medroxyprogesterone acetate is a progestin that induces secretory changes in the endometrium and reduces the risk of endometrial hyperplasia associated with estrogen therapy.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
One tablet daily (conjugated estrogens 0.625 mg/medroxyprogesterone acetate 5 mg) for 14 days, followed by one tablet daily (conjugated estrogens 0.625 mg) for 14 days; continuous cycling. Oral administration.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
None Documented
None Documented
Conjugated estrogens: terminal half-life 10–24 h (accumulation with daily dosing). MPA: terminal half-life 12–33 h (mean ∼17 h).
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Conjugated estrogens and MPA are primarily excreted in urine (∼90% as glucuronide and sulfate conjugates) and feces (∼10% as unabsorbed drug and biliary metabolites).
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Category C
Category C
Estrogen/Progestin Combination
Estrogen